RNAZ Research and Charts

RNAZ - TransCode Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-06-30)

Last 7.80	Change ⇓ -0.17 (-2.13%)	Volume 12,081
	Open 7.78	High 7.99	Low 7.50

8EMA (Daily) 7.72	40EMA (Daily) 6.04	50EMA (Daily) 5.60	STO (Daily) 66.063	MACD Hist (Daily) -0.156
8EMA (Weekly) 6.646	40EMA (Weekly) 3.92	50EMA (Weekly) 3.56	STO (Weekly) 82.896	MACD Hist (Weekly) 1.037


Company Profile
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.